The Series E round of financing, which will have raised about $68.6 million upon completion, will go to the company’s development of soft tissue repair products.
Anulex’s CEO said the money would go toward the company’s Xclose Tissue Repair System and its Rimclose product.
Learn more about the new financing for Anulex Technologies.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
